文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

贝叶斯方法:脓毒症试验的可能前进路径

Bayesian methods: a potential path forward for sepsis trials.
PubMed 文献 · Crit Care · 2023-11-08
一句话结论模拟研究显示,贝叶斯方法在脓毒症试验中合理纳入历史数据可提高统计效能,可能成为重症试验的可行选择。

该模拟研究基于一项已发表的多中心随机临床试验的历史数据,该试验在美国和加拿大开展,评估多黏菌素B血液吸附治疗内毒素性脓毒性休克。历史数据来自该试验中179例成人危重患者的亚组,患者符合脓毒性休克、多器官衰竭且内毒素活性0.60-0.89。模拟新试验纳入150例患者,结果显示在多种基线风险和治疗效应下,通过先验分布合理纳入历史数据可提高统计效能;例如观察到的死亡率风险从44%降至37%时,固定权重75%先验数据的获益概率为96%,自适应权重先验为90%,忽略历史数据则为80%。作者认为贝叶斯方法可能是重症监护试验的可行选择。

要点

  • 模拟新试验150例患者,观察死亡率风险从44%降至37%时,固定权重75%先验数据的获益概率为96%,自适应权重先验为90%,忽略历史数据为80%。
  • 在多种基线风险和治疗效应下,通过先验分布合理纳入历史数据可提高统计效能。
  • 历史数据来自179例成人危重患者亚组,符合脓毒性休克、多器官衰竭且内毒素活性0.60-0.89。
  • 作者认为贝叶斯方法可能是重症监护医学中试验的可行选择,尤其当有益治疗难以发现时。

适用人群与场景

  • 模拟研究基于的历史数据来自成人危重患者,符合脓毒性休克、多器官衰竭且内毒素活性0.60-0.89的179例亚组。
  • 新试验模拟纳入150例患者。

研究设计与关键结果

  • 研究类型为模拟研究,使用已发表的多中心随机临床试验的历史数据,该试验在美国和加拿大开展,评估多黏菌素B血液吸附治疗内毒素性脓毒性休克。
  • 历史数据来自179例成人危重患者亚组,符合脓毒性休克、多器官衰竭且内毒素活性0.60-0.89;试验干预为两次多黏菌素B血液吸附治疗(每次2小时),在入组24小时内完成。
  • 模拟新试验150例患者,在多种基线风险和治疗效应及四种纳入历史数据的方式下,合理纳入历史数据可提高统计效能。
  • 一种可能试验结果:观察到的死亡率风险从44%降至37%时,固定权重75%先验数据的获益概率为96%,自适应权重先验为90%,忽略历史数据为80%。

证据类型、等级与局限

  • 证据类型:模拟研究,基于已发表的多中心随机临床试验的历史数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为贝叶斯方法结合生物学上合理的先验分布使用历史数据,可产生比忽略相关历史数据的传统设计更高统计效能的研究设计。
  • 作者认为贝叶斯方法可能是重症监护医学中试验的可行选择,尤其当有益治疗难以发现时。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Given the success of recent platform trials for COVID-19, Bayesian statistical methods have become an option for complex, heterogenous syndromes like sepsis. However, study design will require careful consideration of how statistical power varies using Bayesian methods across different choices for how historical data are incorporated through a prior distribution and how the analysis is ultimately conducted. Our objective with the current analysis is to assess how different uses of historical data through a prior distribution, and type of analysis influence results of a proposed trial that will be analyzed using Bayesian statistical methods.

METHODS: We conducted a simulation study incorporating historical data from a published multicenter, randomized clinical trial in the US and Canada of polymyxin B hemadsorption for treatment of endotoxemic septic shock. Historical data come from a 179-patient subgroup of the previous trial of adult critically ill patients with septic shock, multiple organ failure and an endotoxin activity of 0.60-0.89. The trial intervention consisted of two polymyxin B hemoadsorption treatments (2 h each) completed within 24 h of enrollment.

RESULTS: In our simulations for a new trial of 150 patients, a range of hypothetical results were observed. Across a range of baseline risks and treatment effects and four ways of including historical data, we demonstrate an increase in power with the use of clinically defensible incorporation of historical data. In one possible trial result, for example, with an observed reduction in risk of mortality from 44 to 37%, the probability of benefit is 96% with a fixed weight of 75% on prior data and 90% with a commensurate (adaptive-weighting) prior; the same data give an 80% probability of benefit if historical data are ignored.

CONCLUSIONS: Using Bayesian methods and a biologically justifiable use of historical data in a prior distribution yields a study design with higher power than a conventional design that ignores relevant historical data. Bayesian methods may be a viable option for trials in critical care medicine where beneficial treatments have been elusive.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Tomlinson G, Al-Khafaji A, Conrad SA, et al. Bayesian methods: a potential path forward for sepsis trials. Crit Care. 2023. PMID: 37940985. doi:10.1186/s13054-023-04717-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。